DOCSLIB.ORG

Gestational Trophoblastic Neoplasia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gestational Trophoblastic Neoplasia NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Gestational Trophoblastic Neoplasia Version 2.2019 — May 6, 2019 NCCN.org Continue Version 2.2019, 05/06/19 © 2019 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN. NCCN Guidelines Index NCCN Guidelines Version 2.2019 Table of Contents Gestational Trophoblastic Neoplasia Discussion *Nadeem R. Abu-Rustum, MD Ω/Chair Patricia J. Eifel, MD § Larissa Nekhlyudov, MD, MPH Memorial Sloan Kettering Cancer Center The University of Texas Dana-Farber/Brigham and Women’s MD Anderson Cancer Center Cancer Center Catheryn M. Yashar, MD §/Vice Chair UC San Diego Moores Cancer Center Christine M. Fisher, MD, MPH § Amanda Nickles Fader, MD Ω University of Colorado Cancer Center The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Sarah Bean, MD ≠ Peter Frederick, MD Ω Duke Cancer Institute Roswell Park Cancer Institute Steven W. Remmenga, MD Ω Fred & Pamela Buffett Cancer Center Kristin Bradley, MD § David K. Gaffney, MD, PhD § University of Wisconsin Huntsman Cancer Institute *R. Kevin Reynolds, MD Ω Carbone Cancer Center at the University of Utah University of Michigan Rogel Cancer Center Susana M. Campos, MD, MPH, MS † Ernest Han, MD, PhD Ω Rachel Sisodia Ω Dana-Farber/Brigham and Women’s City of Hope Comprehensive Cancer Center Cancer Center Massachusetts General Hospital Warner K. Huh, MD Ω Todd Tillmanns, MD Ω Hye Sook Chon, MD Ω University of Alabama at Birmingham Moffitt Cancer Center St. Jude Children’s Research Hospital/ Comprehensive Cancer Center The University of Tennessee Christina Chu, MD Ω *John R. Lurain, III, MD Ω Health Science Center Fox Chase Cancer Center Robert H. Lurie Comprehensive Cancer Stefanie Ueda, MD Ω David Cohn, MD Ω Center of Northwestern University UCSF Helen Diller Family The Ohio State University Comprehensive Comprehensive Cancer Center Cancer Center - James Cancer Hospital and Andrea Mariani, MD Ω Solove Research Institute Mayo Clinic Cancer Center Emily Wyse ¥ Patient Advocate Marta Ann Crispens, MD Ω *David Mutch, MD Ω Vanderbilt-Ingram Cancer Center Siteman Cancer Center at Barnes- Jewish Hospital and Washington NCCN Shari Damast, MD § University School of Medicine Yale Cancer Center/Smilow Cancer Hospital Nicole McMillian, MS Jillian Scavone, PhD Oliver Dorigo, MD, PhD Ω Christa Nagel, MD Ω Stanford Cancer Institute Case Comprehensive Cancer Center/ University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute Ω Gynecologic oncology † Medical oncology NCCN Guidelines Panel Disclosures Continue § Radiotherapy/Radiation oncology ≠ Pathology ¥ Patient advocacy * Discussion Section Writing Committee Version 2.2019, 05/06/19 © 2019 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN. NCCN Guidelines Index NCCN Guidelines Version 2.2019 Table of Contents Gestational Trophoblastic Neoplasia Discussion Gestational Trophoblastic Neoplasia Subcommittee David Mutch, MD Ω/Lead Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine John R. Lurain, III, MD Ω Robert H. Lurie Comprehensive Cancer Center of Northwestern University R. Kevin Reynolds, MD Ω University of Michigan Rogel Cancer Center NCCN Guidelines Panel Disclosures Continue Ω Gynecologic oncology Version 2.2019, 05/06/19 © 2019 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN. NCCN Guidelines Index NCCN Guidelines Version 2.2019 Table of Contents Gestational Trophoblastic Neoplasia Discussion NCCN Gestational Trophoblastic Neoplasia Panel Members NCCN believes that NCCN GTN Subcommittee Members Clinical Trials: the best management for any patient with cancer is in a clinical trial. Hydatidiform Mole (Noninvasive) Participation in clinical trials is Workup, Initial Treatment, Monitoring, Findings and Additional Evaluation (HM-1) especially encouraged. Persistent Post-Molar GTN, Treatment (HM-2) To find clinical trials online at NCCN Member Institutions, click here: Gestational Trophoblastic Neoplasia (GTN) nccn.org/clinical_trials/clinicians.aspx. Workup (GTN-1) Low-Risk GTN Confirmed, Treatment, Monitoring, Follow-up/Surveillance (GTN-2) NCCN Categories of Evidence and Consensus: All recommendations Response Assessment for Low-Risk GTN (GTN-3) are category 2A unless otherwise High-Risk GTN Confirmed; Treatment (GTN-4) indicated. Intermediate Trophoblastic Tumor Confirmed, Treatment, Monitoring and Surveillance (GTN-5) See NCCN Categories of Evidence and Consensus. Principles of Systemic Therapy (GTN-A) Staging (ST-1) The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2019. Version 2.2019, 05/06/19 © 2019 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN. NCCN Guidelines Index NCCN Guidelines Version 2.2019 Table of Contents Gestational Trophoblastic Neoplasia Discussion Updates in Version 2.2019 of the NCCN Guidelines for Gestational Trophoblastic Neoplasia from Version 1.2019 include: • The Discussion has been added to correspond with the algorithm (MS-1) Version 2.2019, 05/06/19 © 2019 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN. UPDATES NCCN Guidelines Index NCCN Guidelines Version 2.2019 Table of Contents Hydatidiform Mole (Noninvasive) Discussion WORKUP INITIAL TREATMENT MONITORING FINDINGS AND ADDITIONAL EVALUATION • H&P hCG assay Normal hCG levels • Pelvic ultrasound twice in a for 3 consecutive • Chest x-ray 3-month assays • Quantitative intervals human chorionic gonadotropin (hCG) Suction dilation • H&P 1 month assay and curettage after initial Complete • CBC differential with (D&C), preferably treatment or partial platelets under ultrasound • hCG assay hydatidiform • Liver/renal/thyroid guidanceb,c every 1–2 mole function tests/ or weeks until chemistry profile Hysterectomyd normalized • Blood type and screen hCG levels Persistent Administer Rho(D) indicate post postmolar immune globulin if molar gestational GTN Rh negative trophoblastic (See HM-2) neoplasia (GTN) aIf chest x-ray positive for metastases, manage as GTN after initial uterine evacuation. bUse largest curette feasible. Sharp curettage after suction. Use uterotonic drugs after initiating evacuation of uterus. Oxytocin receptors may be absent. cProphylactic chemotherapy with methotrexate or dactinomycin may be considered at the time of evacuation of a hydatidiform mole in patients at high risk for postmolar gestational trophoblastic neoplasia (age >40 years, hCG >100,000 mIU/mL, excessive uterine enlargement, and theca lutein cysts >6 cm) when hCG follow-up is unavailable or unreliable (Wang Q, Fu J, Hu L, et al. Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. Cochrane Database Sust Rev 2017 Sep 11;9:CD007289). dHysterectomy may be considered as initial treatment for hydatidiform mole in patients who are older or do not wish to preserve fertility. Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. Version 2.2019, 05/06/19 © 2019 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN. HM-1 NCCN Guidelines Index NCCN Guidelines Version 2.2019 Table of Contents Hydatidiform Mole (Noninvasive) Discussion FINDINGS STAGING TREATMENT MONITORING hCG levels normalize hCG assay every 2 weeks until 3 Consider repeat consecutive No extrauterine D&C normal disease or assays, One or more of the Hysterectomy following indicating followed by post-molar GTN: monthly x 6 • hCG levels plateau months for 4 consecutive • H&P Persistent values over Chemotherapy • Doppler pelvic elevation 3 weeks as in GTN-1 ultrasounde (plateau or rise) • hCG levels rise • Chest x-rayf ≥10% for 3 values over 2 weeks • hCG persistence 6 months after molar evacuation Extrauterine disease Chemotherapy as in GTN-1 Histopathologic diagnosis of choriocarcinoma See GTN-1 and/or Presence of metastatic disease eDoppler pelvic ultrasound to confirm absence of pregnancy, measure uterine size, and
Load more

Recommended publications
  • CASE REPORT Uterine Rupture Due to Invasive Metastatic
    UC Irvine Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health Title Uterine Rupture due to Invasive Metastatic Gestational Trophoblastic Neoplasm Permalink https://escholarship.org/uc/item/7064k01v Journal Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health, 14(5) ISSN 1936-900X Authors Bruner, David I Pritchard, Amy M Clarke, Jonathan E Publication Date 2013 DOI 10.5811/westjem.2013.4.15868 License https://creativecommons.org/licenses/by-nc/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California CASE REPORT Uterine Rupture Due to Invasive Metastatic Gestational Trophoblastic Neoplasm David I. Bruner, MD* * Naval Medical Center Portsmouth, Emergency Medicine Program, Portsmouth, Virginia Amy M. Pritchard, DO† † Naval Medical Hospital Camp Pendleton, Oceanside, California Jonathan Clarke, MD‡ ‡ Naval Medical Center Jacksonville, Jacksonville, Florida Supervising Section Editor: Rick McPheetors, DO Submission history: Submitted January 13, 2013; Revision received April 9, 2013; Accepted April 11, 2013 Full text available through open access at http://escholarship.org/uc/uciem_westjem DOI: 10.5811/westjem.2013.4.15868 While complete molar pregnancies are rare, they are wrought with a host of potential complications to include invasive gestational trophoblastic neoplasia. Persistent gestational trophoblastic disease following molar pregnancy is a potentially fatal complication that must be recognized early and treated aggressively for both immediate and long-term recovery. We present the case of a 21-year-old woman with abdominal pain and presyncope 1 month after a molar pregnancy with a subsequent uterine rupture due to invasive gestational trophoblastic neoplasm. We will discuss the complications of molar pregnancies including the risks and management of invasive, metastatic gestational trophoblastic neoplasia.
    [Show full text]
  • Placental Site Nodule (PSN): an Uncommon Diagnosis with a Common Presentation
    ISSN: 2377-9004 Sneha and Ramesh Kumar. Obstet Gynecol Cases Rev 2021, 8:199 DOI: 10.23937/2377-9004/1410199 Volume 8 | Issue 2 Obstetrics and Open Access Gynaecology Cases - Reviews CASE REPORT Placental Site Nodule (PSN): An Uncommon Diagnosis with a Common Presentation 1* 2 Check for Sneha GS and Ramesh Kumar R updates 1Assistant Professor, Department of Obstetrics and Gynaecology, SDM Medical College and Hospital, SDM University, Karnataka, India 2Professor, Department of Obstetrics and Gynaecology, SDM Medical College and Hospital, SDM University, Karnataka, India *Corresponding author: DR. Sneha GS, Assistant Professor, Department of Obstetrics and Gynaecology, SDM Medical College and Hospital, SDM University, 580009, Dharwad, Karnataka, India ferentiated from aggressive lesions of intermediate tro- Abstract phoblast like placental site trophoblastic tumor and epi- Placental site nodule is an uncommon, benign, generally thelioid trophoblastic tumor and from nontrophoblastic asymptomatic lesion of trophoblastic origin, which may of- ten be detected several months to years after the tenancy diseases like squamous cell carcinoma [1,4]. from which it resulted. PSN usually presents as menorrha- gia, intermenstrual bleeding or an abnormal pap smear. Case Report PSN is benign, but it is important to distinguish it from the A 29-yrs-old female patient para 3, living 3, abor- other benign and malignant lesions like decidua, placental polyp, exaggerated placental site and placental site tropho- tion 5, underwent laprotomy and tubectomy 2 yrs back blastic tumor and squamous cell carcinoma. Follow ups of presented with history of irregular menstrual cycles typical PSNs do not show recurrence or malignant potential. with menorrhagia since 6 months preceded by normal PSN is an uncommon condition which should be suspected cycles.
    [Show full text]
  • New Management of Gestational Trophoblastic Diseases; a Continuum of Moles to Choriocarcinoma: a Review Article
    ©2018 ASP Ins., Afarand Scholarly Publishing Institute, Iran ISSN: 2476-5848; Journal of Obstetrics, Gynecology and Cancer Research. 2018;3(3):123-128. New Management of Gestational trophoblastic diseases; A Continuum of Moles to Choriocarcinoma: A Review Article A R T I C L E I N F O A B S T R A C T Introduction Article Type Gestational trophoblastic diseases (GTD) is the only group of female reproductive neoplasms derived from paternal genetic material (Androgenic origin). GTD Analytical Review Authors is a continuum from benign to malignant; molar pregnancy is benign, but choriocarcinoma 1 MD is malignant. Approximately 45% of patients have metastatic disease when Gestational 1 MD trophoblastic neoplasia (GTN) is diagnosed. GTN is unique in women malignancies because 2 Soheila Aminimoghaddam* MD, PhD it arises from trophoblast but not from genital organs. It is curable with chemotherapy, Nastaran Abolghasem , Tahereh Ashraf- Ganjooie , low-risk GTN completely response to single-agent chemotherapy and does not require Conclusionhistological confirmation. In persistent GTN, clinical staging and workup of metastasis should be performed. The aim of the present study was to review the new management of GTD. In the case of brain, liver, or renal metastases, any woman of reproductive age How to cite this article who presents with an apparent metastatic malignancy of unknown primary site should be screened for the possibility of GTN with a serum HCG level. Excisional biopsy is not indicated to histologically confirm the diagnosis of malignant GTN if the patient is not pregnant and Soheila Aminimoghaddam, Nas- taran Abolghasem, Tahereh As-hraf- has a high HCG value.
    [Show full text]
  • Regulation of Placental Autophagy by the Bcl-2 Family Proteins Myeloid Cell Leukemia Factor 1 (Mcl-1) and Matador/Bcl-2 Related Ovarian Killer (Mtd/Bok)
    Regulation of Placental Autophagy by the Bcl-2 Family Proteins Myeloid Cell Leukemia Factor 1 (Mcl-1) and Matador/Bcl-2 Related Ovarian Killer (Mtd/Bok) by Manpreet Kalkat A thesis submitted in conformity with the requirements for the degree of Master of Science Department of Physiology University of Toronto © Copyright by Manpreet Kalkat, 2010 Regulation of Placental Autophagy by the Bcl-2 Family Proteins Myeloid Cell Leukemia Factor 1 (Mcl-1) and Matador/Bcl-2 Related Ovarian Killer (Mtd/Bok) Manpreet Kalkat Master of Science Department of Physiology University of Toronto 2010 Abstract The process of autophagy is defined as the degradation of cellular cytoplasmic constituents via a lysosomal pathway. Herein I sought to examine the regulation of autophagy in the placental pathologies preeclampsia (PE) and intrauterine growth restriction (IUGR). I hypothesized that the Bcl-2 family proteins Mcl-1L and MtdL regulate placental autophagy and contribute towards dysregulated autophagy in PE. My results demonstrate that Mcl-1L acts to repress autophagy via a Beclin 1 interaction, while MtdL induces autophagy when it interacts with Mcl-1L. My data indicate that while autophagy is elevated in PE, a pathology characterized by oxidative stress, it is decreased in IUGR, a hypoxic pathology. Treatment with sodium nitroprusside to mimic PE caused a decrease in Mcl-1L and an increase in MtdL levels in response to oxidative stress, thereby inducing autophagy. Overall, my data provide insight into the molecular mechanisms contributing to the pathogenesis of preeclampsia. ii Acknowledgments I would like to acknowledge the support my supervisor, Dr. Isabella Caniggia, who has provided me with many valuable lessons that have been instrumental in both my professional and personal growth in this early stage of my scientific career.
    [Show full text]
  • Implantation Site Intermediate Trophoblasts in Placenta Cretas
    Modern Pathology (2004) 17, 1483–1490 & 2004 USCAP, Inc All rights reserved 0893-3952/04 $30.00 www.modernpathology.org Implantation site intermediate trophoblasts in placenta cretas Kyu-Rae Kim1, Sun-Young Jun1, Ji-Young Kim2 and Jae Y Ro1 1Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea and 2Department of Pathology, Cha General Hospital, College of Medicine Pochun Cha University, Seoul, Korea Placenta cretas are defined as abnormal adherences or ingrowths of placental tissue, but their pathogenetic mechanism has not been fully explained. During histologic examination of postpartum uteri, we noticed that the number of implantation site intermediate trophoblasts was increased in the placental bed of placenta cretas. To validate our observation and to address the pathogenetic role of implantation site intermediate trophoblasts in placenta cretas, we examined postpartum uteri with placenta cretas (n ¼ 34) and noncretas (n ¼ 22), obtained from Cesarean or immediate postpartum hysterectomy specimens. Using antibody to CD146, a marker for implantation site intermediate trophoblasts, we found that placenta cretas had significantly thicker layer of implantation site intermediate trophoblasts (230071200 lm) than noncretas (150071200 lm, Po0.025). We also observed that the confluent distribution of cells was more frequent in placenta cretas (97%) than noncretas samples (45%, Po0.001), and that the total number of implantation site intermediate trophoblasts within the superficial myometrium of the placental bed was significantly higher in placenta cretas than noncretas. Using antibodies to Ki-67, Bcl-2 and cleaved caspase-3 to determine the proliferative index and apoptotic rates of implantation site intermediate trophoblasts, we found that they were close to zero in both groups and did not differ significantly.
    [Show full text]
  • From Trophoblast to Human Placenta
    From Trophoblast to Human Placenta (from The Encyclopedia of Reproduction) Harvey J. Kliman, M.D., Ph.D. Yale University School of Medicine I. Introduction II. Formation of the placenta III. Structure and function of the placenta IV. Complications of pregnancy related to trophoblasts and the placenta Glossary amnion the inner layer of the external membranes in direct contact with the amnionic fluid. chorion the outer layer of the external membranes composed of trophoblasts and extracellular matrix in direct contact with the uterus. chorionic plate the connective tissue that separates the amnionic fluid from the maternal blood on the fetal surface of the placenta. chorionic villous the final ramification of the fetal circulation within the placenta. cytotrophoblast a mononuclear cell which is the precursor cell of all other trophoblasts. decidua the transformed endometrium of pregnancy intervillous space the space in between the chorionic villi where the maternal blood circulates within the placenta invasive trophoblast the population of trophoblasts that leave the placenta, infiltrates the endo– and myometrium and penetrates the maternal spiral arteries, transforming them into low capacitance blood channels. Sunday, October 29, 2006 Page 1 of 19 From Trophoblasts to Human Placenta Harvey Kliman junctional trophoblast the specialized trophoblast that keep the placenta and external membranes attached to the uterus. spiral arteries the maternal arteries that travel through the myo– and endometrium which deliver blood to the placenta. syncytiotrophoblast the multinucleated trophoblast that forms the outer layer of the chorionic villi responsible for nutrient exchange and hormone production. I. Introduction The precursor cells of the human placenta—the trophoblasts—first appear four days after fertilization as the outer layer of cells of the blastocyst.
    [Show full text]
  • Rotana Alsaggaf, MS
    Neoplasms and Factors Associated with Their Development in Patients Diagnosed with Myotonic Dystrophy Type I Item Type dissertation Authors Alsaggaf, Rotana Publication Date 2018 Abstract Background. Recent epidemiological studies have provided evidence that myotonic dystrophy type I (DM1) patients are at excess risk of cancer, but inconsistencies in reported cancer sites exist. The risk of benign tumors and contributing factors to tu... Keywords Cancer; Tumors; Cataract; Comorbidity; Diabetes Mellitus; Myotonic Dystrophy; Neoplasms; Thyroid Diseases Download date 07/10/2021 07:06:48 Link to Item http://hdl.handle.net/10713/7926 Rotana Alsaggaf, M.S. Pre-doctoral Fellow - Clinical Genetics Branch, Division of Cancer Epidemiology & Genetics, National Cancer Institute, NIH PhD Candidate – Department of Epidemiology & Public Health, University of Maryland, Baltimore Contact Information Business Address 9609 Medical Center Drive, 6E530 Rockville, MD 20850 Business Phone 240-276-6402 Emails [email protected] [email protected] Education University of Maryland – Baltimore, Baltimore, MD Ongoing Ph.D. Epidemiology Expected graduation: May 2018 2015 M.S. Epidemiology & Preventive Medicine Concentration: Human Genetics 2014 GradCert. Research Ethics Colorado State University, Fort Collins, CO 2009 B.S. Biological Science Minor: Biomedical Sciences 2009 Cert. Biomedical Engineering Interdisciplinary studies program Professional Experience Research Experience 2016 – present Pre-doctoral Fellow National Cancer Institute, National Institutes
    [Show full text]
  • Obstetric Gynecologic Radiology OB001-EB-X MRI Virtual Hysterosalpingography: How to Do It?
    Obstetric Gynecologic Radiology OB001-EB-X MRI Virtual Hysterosalpingography: How to do it? All Day Room: OB Community, Learning Center Participants Patricia M. Carrascosa, MD, Buenos Aires, Argentina (Presenter) Research Consultant, General Electric Company Jimena B. Carpio, MD, Buenos Aires, Argentina (Abstract Co-Author) Nothing to Disclose Javier Vallejos, MD, Vicente Lopez, Argentina (Abstract Co-Author) Nothing to Disclose Carlos Capunay, MD, Buenos Aires, Argentina (Abstract Co-Author) Nothing to Disclose TEACHING POINTS To describe a novel radiation free imaging modality for integral the evaluation of the female pelvis.To be familiar with the advantages, disadvantages, normal anatomy, pathological findings and pitfalls of MRI virtual hysterosalpingography. TABLE OF CONTENTS/OUTLINE A. Description of the procedure. Patient preparation B. MRI image acquisition. Technical parameters. C. Contrast injection protocol. D. Image post-processing and Interpretation E. Diagnostic Imaging F. Indications G. Outcomes OB002-EB-X Common and Uncommon Imaging Presentations of Ectopic Pregnancy All Day Room: OB Community, Learning Center Participants Kellan Schallert, MD, Charlottesville, VA (Presenter) Nothing to Disclose Gia A. Deangelis, MD, Charlottesville, VA (Abstract Co-Author) Nothing to Disclose Arun Krishnaraj, MD, MPH, Charlottesville, VA (Abstract Co-Author) Nothing to Disclose TEACHING POINTS Illustrate the imaging features of various locations and appearances of ectopic pregnancies Highlight classic features, features which portend a poor prognosis, and unique locations of ectopic pregnancies Brief review of the management options TABLE OF CONTENTS/OUTLINE Common and Uncommon Imaging Presentations of Ectopic PregnancyTeaching Points Illustrate the imaging features of various locations and appearances of ectopic pregnancy Highlight classic features, features which portend a poor prognosis, and unique locations of ectopic pregnancies Brief review of the management optionsOutline1.
    [Show full text]
  • Gestational Trophoblastic Disease
    GESTATIONAL Danielle Krause, MD PGY3 TROPHOBLASTIC Obstetrics & DISEASE Gynecology Gestational Trophoblastic Disease ■ Spectrum of interrelated conditions ■ All arise from the placenta ■ Abnormal trophoblastic proliferation ■ All secrete human chorionic gonadotropin (hCG) – Excellent biomarker for disease progression and treatment response Benign •Partial hydatiform mole •Complete hydatiform mole Gestational Trophoblastic Malignant Disease •Invasive and metastatic mole •Choriocarcinoma •Placental Site Trophoblastic Tumor •Epithelioid Trophoblastic Tumor •New: Atypical placental site nodule Epidemiology ■ Hydatiform mole (Benign) – 1/1000 pregnancies worldwide – High-income populations ■ Complete moles: 1-3/1000 ■ Partial moles: 3/1000 – More common at extremes of reproductive age (<15 and >45yo) – History of previous molar pregnancy 10x risk *Biggest RF ■ Choriocarcinoma – North America/Europe: 1/40,000 – Southeast Asia/Japan: 3-4/40,000 Benign •Partial hydatiform mole •Complete hydatiform mole Gestational Trophoblastic Malignant Disease •Invasive and metastatic mole •Choriocarcinoma •Placental Site Trophoblastic Tumor •Epithelioid Trophoblastic Tumor •New: Atypical placental site nodule Review of Fertilization 1. Sperm head binds to zona pellucida (glycoprotein layer surrounding the oocyte) 2. Acrosome reaction = hydrolytic enzymes released at the head of the sperm 3. Penetration of the zona pellucida 4. Cell membrane of sperm and egg fuse 5. Sperm nucleus/cytoplasm released into the egg 6. Completion of second meiotic division by the
    [Show full text]
  • Intraplacental Choriocarcinoma: a Report of Two Cases
    J Clin Pathol: first published as 10.1136/jcp.41.10.1085 on 1 October 1988. Downloaded from J Clin Pathol 1988;41:1085-1088 Intraplacental choriocarcinoma: a report of two cases H FOX,* R N LAURINIt From the *Department ofPathology, University ofManchester, and tDivision ofDevelopmental and Paediatric Pathology, Institut de Pathologie, Centre Hospitalier Universitaire, Vaudois, Lausanne, Switzerland SUMMARY Two examples ofintraplacental choriocarcinoma are described. Both were small and had arisen in otherwise normal third trimester placentas. The covering mantle ofmany ofthe villi adjacent to the choriocarcinomas was formed, either focally or wholly, of neoplastic trophoblastic tissue: it is only at this stage of the development of a choriocarcinoma that villous structures are present, and a study ofthese cases adds further evidence for an origin ofchoriocarcinoma from villous trophoblast. Intraplacental choriocarcinomas can give rise to both maternal and fetal metastases during pregnancy, and it is suggested that such lesions also serve as an origin for those choriocarcinomas which follow a term pregnancy. In western countries about 20% of gestational Histopathologicalfindings choriocarcinomas follow an apparently normal full Sections from the reddish area showed a typical term pregnancy.' It has been generally assumed that in choriocarcinoma (fig 1); in some areas there was a such cases the trophoblastic neoplasm arises either sharp transition from choriocarcinoma to normal villi from villous tissue which has been retained within the
    [Show full text]
  • Review Article
    ISSN 2091-2889 (Online) ISSN 2091-2412 (Print) Journal of Chitwan Medical College 2013; 3(4): 4-11 Available online at: www.jcmc.cmc.edu.np REVIEW ARTICLE GESTATIONAL TROPHOBLASTIC DISEASE JP Deep 1*, LB Sedhai 1, J Napit 1 and J Pariyar 2 1 Department of Obstetrics and Gynecology, Chitwan Medical College Teaching Hospital, Bharatpur-10, Chitwan, Nepal. 2 Gynecologic Oncology Unit, BP Koirala Memorial Cancer Hospital, Chitwan, Nepal. *Correspondence to : Dr Jagat P Deep, Chitwan Medical College Teaching Hospital, Bharatpur-10, Chitwan, Nepal. Email: [email protected] ABSTRACT Gestational trophoblastic disease (GTD) is a group of tumors that arise from placental tissue and secrete β-hCG. GTD is a combination of benign or invasive mole and malignant known as Gestational Trophoblastic Neoplasia (GTN). Prevalence, diagnosis and treatment of GTD have drastically changed in recent years. Key Words: Chemotherapy, Gestational Trophoblastic Disease (GTD), Gestational Trophoblastic Neoplasia (GTN), Hys- terectomy & Molar Pregnancy. INTRODUCTION Gestational trophoblastic disease (GTD) comprises a group of Pathology of Gestational Trophoblastic Disease interrelated conditions that arise from placental trophoblastic All type of gestational trophoblastic disease is derived from tissue after normal or abnormal fertilization. It comprises a the placenta. GTD is a combination of benign and malignant spectrum of clinical entities ranging from non-invasive molar or invasive disease. Hydatidiform moles and choriocarcinoma pregnancy, to metastatic gestational
    [Show full text]
  • Pattern of Gynaecological Malignancies in a Tertiary Care Hospital
    Open Journal of Obstetrics and Gynecology, 2019, 9, 449-457 http://www.scirp.org/journal/ojog ISSN Online: 2160-8806 ISSN Print: 2160-8792 Pattern of Gynaecological Malignancies in a Tertiary Care Hospital Sayma Afroz*, Gulshan Ara, Fahmida Sultana Deparment of Obstetrics & Gynaecology, Enam Medical College & Hospital, Dhaka, Bangladesh How to cite this paper: Afroz, S., Ara, G. Abstract and Sultana, F. (2019) Pattern of Gynaeco- logical Malignancies in a Tertiary Care Background: Gynaecological malignancies are the second most common Hospital. Open Journal of Obstetrics and cancer of females after cancer breast. Gynaecological malignancies contribute Gynecology, 9, 449-457. significantly to cancer burden and have a higher rate of mortality and mor- https://doi.org/10.4236/ojog.2019.94044 bidity. Carcinoma cervix is the commonest gynaecological malignancy in de- Received: March 8, 2019 veloping countries while in developed countries, ovarian cancer is the com- Accepted: April 8, 2019 monest. Comprehensive statistics on gynecologic malignancies reported from Published: April 11, 2019 Bangladesh are deficient. This study was performed to ascertain the profile of Copyright © 2019 by author(s) and gynecologic cancers reported at our center regarding demography, the Scientific Research Publishing Inc. frequency of involvement at various sites, clinical presentation, incidence, This work is licensed under the Creative histologic subtypes and stage at presentation. Methods: This is a retrospec- Commons Attribution International tive study where the records of the Departments of Gynecology and Patholo- License (CC BY 4.0). http://creativecommons.org/licenses/by/4.0/ gy at Enam Medical College & Hospital, Dhaka, Bangladesh were retrospec- Open Access tively reviewed to identify all cases of Gynecologic malignancies and to de- termine the pattern of gynaecological malignancies identified between Janu- ary 2015 and December, 2018.
    [Show full text]